Literature DB >> 27590136

Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress.

Helena M Abelaira1, Gislaine Z Réus2, Zuleide M Ignácio1, Maria Augusta B Dos Santos1, Airam B de Moura1, Danyela Matos1, Júlia P Demo1, Júlia B I da Silva1, Lucineia G Danielski3, Fabricia Petronilho3, André F Carvalho4, João Quevedo1,5,6,7.   

Abstract

Studies indicated that mammalian target of rapamycin (mTOR), oxidative stress, and inflammation are involved in the pathophysiology of major depressive disorder (MDD). Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been identified as a novel MDD therapy; however, the antidepressant mechanism is not fully understood. In addition, the effects of ketamine after mTOR inhibition have not been fully investigated. In the present study, we examined the behavioral and biochemical effects of ketamine in the prefrontal cortex (PFC), hippocampus, amygdala, and nucleus accumbens after inhibition of mTOR signaling in the PFC. Male adult Wistar rats received pharmacological mTOR inhibitor, rapamycin (0.2 nmol) or vehicle into the PFC and then a single dose of ketamine (15 mg/kg, i.p.). Immobility was assessed in forced swimming tests, and then oxidative stress parameters and inflammatory markers were evaluated in the brain and periphery. mTOR activation in the PFC was essential to ketamine's antidepressant-like effects. Ketamine increased lipid damage in the PFC, hippocampus, and amygdala. Protein carbonyl was elevated in the PFC, amygdala, and NAc after ketamine administration. Ketamine also increased nitrite/nitrate in the PFC, hippocampus, amygdala, and NAc. Myeloperoxidase activity increased in the hippocampus and NAc after ketamine administration. The activities of superoxide dismutase and catalase were reduced after ketamine administration in all brain areas studied. Inhibition of mTOR signaling pathways by rapamycin in the PFC was required to protect against oxidative stress by reducing damage and increasing antioxidant enzymes. Finally, the TNF-α level was increased in serum by ketamine; however, the rapamycin plus treatment group was not able to block this increase. Activation of mTOR in the PFC is involved in the antidepressant-like effects of ketamine; however, the inhibition of this pathway was able to protect certain brain areas against oxidative stress, without affecting inflammation parameters.

Entities:  

Keywords:  Animal model; Inflammation; Ketamine; Major depressive disorder; Oxidative stress; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27590136     DOI: 10.1007/s12035-016-0071-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  95 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  The immune response to surgery and trauma: Implications for treatment.

Authors:  Paul E Marik; Mark Flemmer
Journal:  J Trauma Acute Care Surg       Date:  2012-10       Impact factor: 3.313

4.  Effects of chronic mild stress on the oxidative parameters in the rat brain.

Authors:  Giancarlo Lucca; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Francieli Vuolo; Fabrícia Petronilho; Felipe Dal-Pizzol; Elaine C Gavioli; João Quevedo
Journal:  Neurochem Int       Date:  2009-01-08       Impact factor: 3.921

Review 5.  New paradigms for treatment-resistant depression.

Authors:  Carlos Zarate; Ronald S Duman; Guosong Liu; Simone Sartori; Jorge Quiroz; Harald Murck
Journal:  Ann N Y Acad Sci       Date:  2013-07       Impact factor: 5.691

Review 6.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

7.  Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.

Authors:  David R Fernandez; Tiffany Telarico; Eduardo Bonilla; Qing Li; Sanjay Banerjee; Frank A Middleton; Paul E Phillips; Mary K Crow; Stefanie Oess; Werner Muller-Esterl; Andras Perl
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects.

Authors:  Dharmendra B Goswami; Courtney S Jernigan; Agata Chandran; Abiye H Iyo; Warren L May; Mark C Austin; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-12-20       Impact factor: 5.067

10.  Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Authors:  Zhi-Wei Lai; Rebecca Borsuk; Ashwini Shadakshari; Jianghong Yu; Maha Dawood; Ricardo Garcia; Lisa Francis; Hajra Tily; Adam Bartos; Stephen V Faraone; Paul Phillips; Andras Perl
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

View more
  8 in total

Review 1.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

2.  Unpredictable Chronic Mild Stress Paradigm Established Effects of Pro- and Anti-inflammatory Cytokine on Neurodegeneration-Linked Depressive States in Hamsters with Brain Endothelial Damages.

Authors:  Ennio Avolio; Gilda Fazzari; Maria Mele; Raffaella Alò; Merylin Zizza; Wei Jiao; Anna Di Vito; Tullio Barni; Maurizio Mandalà; Marcello Canonaco
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

3.  Noise Induced Depression-Like Behavior, Neuroinflammation and Synaptic Plasticity Impairments: The Protective Effects of Luteolin.

Authors:  Yuan Cheng; Xiaoxuan Wang; Yinghua Yu; Jingxue Gu; Maofang Zhao; Qian Fu; Yilin Song; Yi Liu
Journal:  Neurochem Res       Date:  2022-08-17       Impact factor: 4.414

Review 4.  Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation.

Authors:  Gislaine Z Reus; Airam B de Moura; Ritele H Silva; Wilson R Resende; Joao Quevedo
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

Review 5.  The Endoplasmic Reticulum Stress Response in Neuroprogressive Diseases: Emerging Pathophysiological Role and Translational Implications.

Authors:  Gerwyn Morris; Basant K Puri; Ken Walder; Michael Berk; Brendon Stubbs; Michael Maes; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-03-29       Impact factor: 5.590

Review 6.  Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.

Authors:  Chun Yang; Jianjun Yang; Ailin Luo; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2019-11-07       Impact factor: 6.222

Review 7.  Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates.

Authors:  Roberta Eduarda Grolli; Maiqueli Eduarda Dama Mingoti; Amanda Gollo Bertollo; Adriana Remião Luzardo; João Quevedo; Gislaine Zilli Réus; Zuleide Maria Ignácio
Journal:  Mol Neurobiol       Date:  2021-01-06       Impact factor: 5.590

8.  Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.

Authors:  Emma Kopra; Valeria Mondelli; Carmine Pariante; Naghmeh Nikkheslat
Journal:  J Psychopharmacol       Date:  2021-06-26       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.